Epoetin beta pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats

European Journal of Pharmacology

Volumn 767, Issue , 2015, Pages 10-16

  Serizawa, Kenichi ^a   Yogo, Kenji ^a   Tashiro, Yoshihito ^a   Aizawa, Ken ^a   Kawasaki, Ryohei ^a   Hirata, Michinori ^a   Endo, Koichi ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Chronic kidney disease; Continuous erythropoietin receptor activator; Endothelial dysfunction; Epoetin beta pegol; Erythropoietin; Flow mediated dilation

Indexed keywords

ANTIANEMIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPOETIN BETA PEGOL; GLYCERYL TRINITRATE; HEMOGLOBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; UNCLASSIFIED DRUG; 3-NITROTYROSINE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CREATININE; ERYTHROPOIETIN; MACROGOL DERIVATIVE; NOX4 PROTEIN, RAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY DILATATION; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME PHOSPHORYLATION; FEMORAL ARTERY; FEMORAL ARTERY FLOW; HEART PROTECTION; HEART RATE; HEMOGLOBIN BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; VASODILATATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BLOOD; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; KIDNEY FUNCTION TEST; METABOLISM; NEPHRECTOMY; PROTEINURIA; URINE; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CREATININE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; FEMORAL ARTERY; HEART RATE; HEMOGLOBINS; KIDNEY FUNCTION TESTS; MALE; NADPH OXIDASE; NEPHRECTOMY; NITRIC OXIDE SYNTHASE TYPE III; NITROGLYCERIN; POLYETHYLENE GLYCOLS; PROTEINURIA; RATS; RENAL INSUFFICIENCY, CHRONIC; TYROSINE; ULTRASONOGRAPHY; VASODILATION;

EID: 84946555058     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.09.034     Document Type: Article

References (51)

1. A.K. Abiose, W.S. Aronow, H. Moreno Jr., C.K. Nair, T.F. Blaschke, and B.B. Hoffman Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin Am. J. Ther. 14 2007 427 434
2. K. Aizawa, Y. Tashiro, M. Hirata, S. Takeda, R. Kawasaki, and K. Endo Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats J. Nephrol. 27 2014 395 401
3. D.R. Alessi, and P. Cohen Mechanism of activation and function of protein kinase B Curr. Opin. Genet. Dev. 8 1998 55 62
4. R.K. Ambasta, P. Kumar, K.K. Griendling, H.H. Schmidt, R. Busse, and R.P. Brandes Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase J. Biol. Chem. 279 2004 45935 45941
5. F.H. Bahlmann, R. Song, S.M. Boehm, M. Mengel, R. von Wasielewski, C. Lindschau, T. Kirsch, K. de Groot, R. Laudeley, E. Niemczyk, F. Guler, J. Menne, H. Haller, and D. Fliser Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure Circulation 110 2004 1006 1012
6. J.S. Beckman, and W.H. Koppenol Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly Am. J. Physiol. 271 1996 C1424 C1437
7. S.V. Brodsky, O. Gealekman, J. Chen, F. Zhang, N. Togashi, M. Crabtree, S.S. Gross, A. Nasjletti, and M.S. Goligorsky Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen Circ. Res. 94 2004 377 384
8. M.C. Corretti, T.J. Anderson, E.J. Benjamin, D. Celermajer, F. Charbonneau, M.A. Creager, J. Deanfield, H. Drexler, M. Gerhard-Herman, D. Herrington, P. Vallance, J. Vita, R. Vogel, and F. International Brachial Artery Reactivity Task Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force J. Am. Coll. Cardiol. 39 2002 257 265
9. S.S. DeLoach, and E.R. Mohler 3rd Peripheral arterial disease: a guide for nephrologists Clin. J. Am. Soc. Nephrol. 2 2007 839 846
10. N. Dhaun, J. Goddard, and D.J. Webb The endothelin system and its antagonism in chronic kidney disease J. Am. Soc. Nephrol. 17 2006 943 955
11. J. Downward Mechanisms and consequences of activation of protein kinase B/Akt Curr. Opin. Cell Biol. 10 1998 262 267
12. T.B. Drueke, F. Locatelli, N. Clyne, K.U. Eckardt, I.C. Macdougall, D. Tsakiris, H.U. Burger, and A. Scherhag Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl. J. Med. 355 2006 2071 2084
13. B. Fuste, M. Serradell, G. Escolar, A. Cases, R. Mazzara, R. Castillo, A. Ordinas, and M. Diaz-Ricart Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro Thromb. Haemost. 88 2002 678 685
14. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl. J. Med. 351 2004 1296 1305
15. G. Grassi, F. Quarti-Trevano, G. Seravalle, F. Arenare, M. Volpe, S. Furiani, R. Dell'Oro, and G. Mancia Early sympathetic activation in the initial clinical stages of chronic renal failure Hypertension 57 2011 846 851
16. K.K. Griendling, D. Sorescu, and M. Ushio-Fukai NAD(P)H oxidase: role in cardiovascular biology and disease Circ. Res. 86 2000 494 501
17. R.J. Gryglewski, R.M. Palmer, and S. Moncada Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor Nature 320 1986 454 456
18. A. Hacisevki, A. Gonenc, S. Sezer, S. Karakan, B. Simsek, and M. Torun Accumulation of an endogenous inhibitor of nitric oxide synthesis and oxidative DNA damage in end-stage renal disease Clin. Lab. 59 2013 1353 1361
19. M. Jarsch, M. Brandt, M. Lanzendorfer, and A. Haselbeck Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay Pharmacology 81 2008 63 69
20. A. Khoshdel, S. Carney, A. Gillies, A. Mourad, B. Jones, R. Nanra, and P. Trevillian Potential roles of erythropoietin in the management of anaemia and other complications diabetes Diabetes Obes. Metab. 10 2008 1 9
21. M. Kuwahara, S. Hasumi, S. Mandai, T. Tanaka, S. Shikuma, W. Akita, Y. Mori, and S. Sasaki Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients Clin. Exp. Nephrol. 18 2013 755 762
22. F. Locatelli, and B. Reigner C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease Expert Opin. Investig. Drugs 16 2007 1649 1661
23. G.A. Mashour, and R.J. Boock Effects of shear stress on nitric oxide levels of human cerebral endothelial cells cultured in an artificial capillary system Brain Res. 842 1999 233 238
24. T.N. McAllister, and J.A. Frangos Steady and transient fluid shear stress stimulate NO release in osteoblasts through distinct biochemical pathways J. Bone Miner. Res. 14 1999 930 936
25. P.A. McCullough, H.X. Barnhart, J.K. Inrig, D. Reddan, S. Sapp, U.D. Patel, A.K. Singh, L.A. Szczech, and R.M. Califf Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease Am. J. Nephrol. 37 2013 549 558
26. J.J. McMurray, H. Uno, P. Jarolim, A.S. Desai, D. de Zeeuw, K.U. Eckardt, P. Ivanovich, A.S. Levey, E.F. Lewis, J.B. McGill, P. Parfrey, H.H. Parving, R.M. Toto, S.D. Solomon, and M.A. Pfeffer Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT) Am. Heart J. 162 2011 748 755 e743
27. E.R. Mohler 3rd, Z. Lifeng, E. Medenilla, W. Rogers, B. French, A. Bantly, J.S. Moore, H. Yonghong, M. Murashima, and J.S. Berns Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease Vasc. Med. 16 2011 183 189
28. G. Muller, and H. Morawietz NAD(P)H oxidase and endothelial dysfunction Horm. Metab. Res. 41 2009 152 158
29. T. Namikoshi, N. Tomita, M. Satoh, T. Sakuta, A. Kuwabara, S. Kobayashi, Y. Higuchi, F. Nishijima, and N. Kashihara Oral adsorbent AST-120 ameliorates endothelial dysfunction independent of renal function in rats with subtotal nephrectomy Hypertens. Res. 32 2009 194 200
30. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, M.E. Cooper, D. de Zeeuw, K.U. Eckardt, J.M. Feyzi, P. Ivanovich, R. Kewalramani, A.S. Levey, E.F. Lewis, J.B. McGill, J.J. McMurray, P. Parfrey, H.H. Parving, G. Remuzzi, A.K. Singh, S.D. Solomon, and R. Toto A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl. J. Med. 361 2009 2019 2032
31. R. Provenzano, A. Besarab, I.C. Macdougall, D.H. Ellison, A.P. Maxwell, W. Sulowicz, M. Klinger, B. Rutkowski, R. Correa-Rotter, F.C. Dougherty, and B.A.S. Investigators The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study Clin. Nephrol. 67 2007 306 317
32. A.E. Raine Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy Lancet 1 1988 97 100
33. K. Serizawa, K. Yogo, K. Aizawa, Y. Tashiro, and N. Ishizuka Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats Cardiovasc. Diabetol. 10 2011 105
34. K. Serizawa, K. Yogo, K. Aizawa, Y. Tashiro, Y. Takahari, K. Sekine, T. Suzuki, N. Ishizuka, and H. Ishida Paclitaxel-induced endothelial dysfunction in living rats is prevented by nicorandil via reduction of oxidative stress J. Pharmacol. Sci. 119 2012 349 358
35. L. Serrander, L. Cartier, K. Bedard, B. Banfi, B. Lardy, O. Plastre, A. Sienkiewicz, L. Forro, W. Schlegel, and K.H. Krause NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation Biochem. J. 406 2007 105 114
36. D. Shimbo, C. Grahame-Clarke, Y. Miyake, C. Rodriguez, R. Sciacca, M. Di Tullio, B. Boden-Albala, R. Sacco, and S. Homma The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort Atherosclerosis 192 2007 197 203
37. A.K. Singh, L. Szczech, K.L. Tang, H. Barnhart, S. Sapp, M. Wolfson, and D. Reddan Correction of anemia with epoetin alfa in chronic kidney disease N Engl. J. Med. 355 2006 2085 2098
38. D. Sorescu, D. Weiss, B. Lassegue, R.E. Clempus, K. Szocs, G.P. Sorescu, L. Valppu, M.T. Quinn, J.D. Lambeth, J.D. Vega, W.R. Taylor, and K.K. Griendling Superoxide production and expression of nox family proteins in human atherosclerosis Circulation 105 2002 1429 1435
39. A.C. Souza, R.A. Volpini, M.H. Shimizu, T.R. Sanches, N.O. Camara, P. Semedo, C.E. Rodrigues, A.C. Seguro, and L. Andrade Erythropoietin prevents sepsis-related acute kidney injury in rats by inhibiting NF-kappaB and upregulating endothelial nitric oxide synthase Am. J. Physiol. Renal Physiol. 302 2012 F1045 F1054
40. K. Sriram, B.Y. Salazar Vazquez, A.G. Tsai, P. Cabrales, M. Intaglietta, and D.M. Tartakovsky Autoregulation and mechanotransduction control the arteriolar response to small changes in hematocrit Am. J. Physiol. Heart Circ. Physiol. 303 2012 H1096 H1106
41. L.A. Szczech, H.X. Barnhart, J.K. Inrig, D.N. Reddan, S. Sapp, R.M. Califf, U.D. Patel, and A.K. Singh Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes Kidney Int. 74 2008 791 798
42. L.A. Szczech, H.X. Barnhart, S. Sapp, G.M. Felker, A. Hernandez, D. Reddan, R.M. Califf, J.K. Inrig, U.D. Patel, and A.K. Singh A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment Kidney Int. 77 2010 239 246
43. H. Toba, Y. Kojima, J. Wang, K. Noda, W. Tian, M. Kobara, and T. Nakata Erythropoietin attenuated vascular dysfunction and inflammation by inhibiting NADPH oxidase-derived superoxide production in nitric oxide synthase-inhibited hypertensive rat aorta Eur. J. Pharmacol. 691 2012 190 197
44. H. Toba, M. Morishita, C. Tojo, A. Nakano, Y. Oshima, Y. Kojima, M. Yoshida, K. Nakashima, J. Wang, M. Kobara, and T. Nakata Recombinant human erythropoietin ameliorated endothelial dysfunction and macrophage infiltration by increasing nitric oxide in hypertensive 5/6 nephrectomized rat aorta Eur. J. Pharmacol. 656 2011 81 87
45. P.T. Vlagopoulos, H. Tighiouart, D.E. Weiner, J. Griffith, D. Pettitt, D.N. Salem, A.S. Levey, and M.J. Sarnak Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease J. Am. Soc. Nephrol. 16 2005 3403 3410
46. J. Wang, H. Toba, Y. Morita, K. Nakashima, K. Noda, W. Tian, M. Kobara, and T. Nakata Endothelial dysfunction, macrophage infiltration and NADPH oxidase-dependent superoxide production were attenuated by erythropoietin in streptozotocin-induced diabetic rat aorta Pharmacology 91 2013 48 58
47. W.S. Yang, J.W. Chang, N.J. Han, and S.K. Park Darbepoetin alfa suppresses tumor necrosis factor-alpha-induced endothelin-1 production through antioxidant action in human aortic endothelial cells: role of sialic acid residues Free Radic. Biol. Med. 50 2011 1242 1251
48. J. Yeboah, J.R. Crouse, F.C. Hsu, G.L. Burke, and D.M. Herrington Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study Circulation 115 2007 2390 2397
49. J. Yeboah, A.R. Folsom, G.L. Burke, C. Johnson, J.F. Polak, W. Post, J.A. Lima, J.R. Crouse, and D.M. Herrington Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis Circulation 120 2009 502 509
50. M.I. Yilmaz, A. Sonmez, M. Saglam, M. Gulec, S. Kilic, T. Eyileten, K. Caglar, Y. Oguz, A. Vural, M. Yenicesu, and C. Zoccali Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease Kidney Int. 75 2009 1316 1321
51. L.V. d'Uscio, L.A. Smith, A.V. Santhanam, D. Richardson, K.A. Nath, and Z.S. Katusic Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin Hypertension 49 2007 1142 1148